Hologic, Inc. (NASDAQ:HOLX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Hologic, Inc. has received a consensus rating of "Moderate Buy" from eighteen research firms, with nine analysts recommending a buy and eight a hold.
• The average 1-year price target for Hologic's stock is $80.15, with some analysts setting targets as high as $90.00.
• In recent earnings, Hologic reported an EPS of $1.08, surpassing analysts' expectations, and has provided guidance for Q4 2025 of 1.090-1.120 EPS.

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eighteen research firms that are presently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $80.1538.

HOLX has been the subject of several research analyst reports. Mizuho set a $75.00 price target on shares of Hologic in a report on Thursday, July 31st. Weiss Ratings reissued a "hold (c-)" rating on shares of Hologic in a report on Wednesday, October 8th. Evercore ISI set a $78.00 price target on shares of Hologic and gave the company an "outperform" rating in a report on Tuesday, October 7th. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Wednesday, October 1st. Finally, Argus boosted their price target on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a report on Friday, September 19th.

Hologic Price Performance

HOLX opened at $69.85 on Friday. The company has a fifty day moving average price of $67.11 and a two-hundred day moving average price of $63.51. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic has a 52 week low of $51.90 and a 52 week high of $84.39. The firm has a market capitalization of $15.54 billion, a PE ratio of 28.98, a P/E/G ratio of 2.35 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business earned $1.06 EPS. The business's quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts anticipate that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the business's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently added to or reduced their stakes in HOLX. Farther Finance Advisors LLC lifted its position in Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock valued at $113,000 after acquiring an additional 335 shares in the last quarter. SG Americas Securities LLC lifted its position in Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock valued at $594,000 after acquiring an additional 5,172 shares in the last quarter. Blue Trust Inc. lifted its position in Hologic by 26.8% in the 1st quarter. Blue Trust Inc. now owns 7,637 shares of the medical equipment provider's stock valued at $472,000 after acquiring an additional 1,616 shares in the last quarter. Abundance Wealth Counselors lifted its position in Hologic by 10.5% in the 1st quarter. Abundance Wealth Counselors now owns 11,994 shares of the medical equipment provider's stock valued at $741,000 after acquiring an additional 1,144 shares in the last quarter. Finally, Praxis Investment Management Inc. bought a new stake in Hologic in the 1st quarter valued at $240,000. 94.73% of the stock is owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.